Clinical trials: Overweight With Comorbidities
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Obesity
Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients. Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist…
- Trial name
- NCT00325546
- Testing
- Rimonabant (SR141716)
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus With Circulatory Complciation
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
The study is to assess the safety and feasibility of chemical denervation of multiple artery beds for the treatment of Type 2 diabetes (T2DM) and its comorbidities.
- Trial name
- NECTAR (NCT04232774)
- Testing
- The Neurotronic arterial ablation catheter
- Where
- Paraguay
- Volunteers
- 22 people
- Sponsor
- Neurotronic, Inc.
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2…
- Trial name
- NCT06972459
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Binge Eating Disorder, Cognitive Therapy/Methods
The Psychological Treatment of Overweight Binge Eaters Minority Supplement
Cognitive-behavioral therapy (CBT) has documented efficacy for the treatment of binge eating disorder (BED). Interpersonal psychotherapy (IPT) has been shown to reduce binge eating but its long-term impact and time course on…
- Conditions
- Binge Eating Disorder, Cognitive Therapy/Methods, Mental Disorders/Epidemiology, Obesity/Epidemiology
- Trial name
- NCT01208259
- Testing
- Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT)
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obesity, Obese
Cost-effectiveness Study of a Multidisciplinary Weight Loss Method to Improve the Health Condition of Obese Patients
Prospective, observational, multicenter study based on a registry of patients with obesity and associated comorbidities undergoing a standardized multidisciplinary weight loss method with a 2-year follow-up.
- Trial name
- PRONOCOST (NCT05833464)
- Where
- Argentina
- Sponsor
- Protein Supplies SL
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Obese Patients (BMI ≥ 30 kg/m²), Obese Patients
Modifications to Gastric Sleeve: Implications for GRED and Quality of Life
This is a prospective randomized clinical trial evaluating the impact of antrum and fundus calibration during laparoscopic vertical gastrectomy (VG) on postoperative gastroesophageal reflux disease (GERD), quality of life, and…
- Conditions
- Obese Patients (BMI ≥ 30 kg/m²), Obese Patients, Obese Patients With Bariatric Surgery, Obese With Comorbidities
- Trial name
- NCT07070908
- Testing
- Antrum calibration, Fudus calibration, No antrum calibration
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Hospital San Juan de Dios Tenerife
Obesity
Evaluation of Health Improvement in Obese Patients With Obesity-related Comorbidities Followed by EndoZip Procedure
multicenter, prospective, single arm study will include up to 45 patients, (up to 30 patients per site), aimed at evaluating the performance of the EndoZip System in obese patients with type 2 diabetes and / or hypertension who…
- Trial name
- CL00010 (NCT05623163)
- Testing
- EndoZip System
- Where
- 2 sites in Czechia, Italy
- Volunteers
- 38 people
- Sponsor
- Nitinotes Surgical Ltd.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
- Trial name
- NCT06075667
- Testing
- Tirzepatide
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Obesity, Weight Loss
Obese Patients With or Without Comorbidities (RIO-North America)
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
- Trial name
- NCT00029861
- Testing
- Rimonabant (SR141716)
- Where
- 51 sites in United States, Canada
- Volunteers
- 3,045 people
- Sponsor
- Sanofi
Overweight, Obesity
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine…
- Trial name
- UNLIMITED (NCT05209984)
- Testing
- ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg, ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg, SIB Group Sibus (Sibutramine) 15mg
- Where
- 2 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
COVID19, Diabetes Mellitus
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
The disease caused by SARS-CoV-2, has derived a pandemic in which its evolution and complications depend on the immune capacity of the host.
- Conditions
- COVID19, Diabetes Mellitus, Hypertension, Obesity
- Trial name
- NCT04507867
- Testing
- Nutritional support system (NSS), Conventional nutritional support designed by hospital nutritionists
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Anahuac University
PCOS (Polycystic Ovary Syndrome), Obese Adolescents
Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)
This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored…
- Conditions
- PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents
- Trial name
- Beef+ (NCT07780188)
- Testing
- Beef+
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Texas A&M University
Alcohol Use Disorder (AUD), Overweight or Obese
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight/obesity (AUD-OOB) to receive either a sub-cutaneous injection of…
- Conditions
- Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
- Trial name
- NCT07292519
- Testing
- Tirzepatide, Take Control CBT Module
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- South West Sydney Local Health District
Binge Eating Disorder, Cognitive Therapy/Methods
Psychological Treatment of Overweight Binge Eaters
Cognitive-behavioral therapy (CBT) has documented efficacy for the treatment of binge eating disorder (BED). Interpersonal psychotherapy (IPT) has been shown to reduce binge eating but its long-term impact and time course on…
- Conditions
- Binge Eating Disorder, Cognitive Therapy/Methods, Mental Disorders/Epidemiology, Obesity/Epidemiology
- Trial name
- NCT01208272
- Testing
- Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT)
- Where
- 2 sites in United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obesity
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
The study is intended to understand the distribution of different obesity classes and obesity related diseases (diseases that present along with obesity) in patients with body mass index (BMI) ≥ 30 kg/m^2.
- Trial name
- ExplorEUEast (NCT05795166)
- Testing
- No treatment given
- Volunteers
- 1,241 people
- Sponsor
- Novo Nordisk A/S